# Safety and Efficacy of PD-1 Inhibitors in Patients With Liver Transplant

> **NCT03966209** · PHASE1 · UNKNOWN · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Hepatocellular Carcinoma
- Liver Transplantation

## Interventions

- **DRUG:** JS001(PD-1 inhibitor)

## Key facts

- **NCT ID:** NCT03966209
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-05-01
- **Primary completion:** 2021-04-30
- **Final completion:** 2022-10-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2019-05-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03966209

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03966209, "Safety and Efficacy of PD-1 Inhibitors in Patients With Liver Transplant". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03966209. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*